PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Collinson, F, Brown, S, Buckley, H orcid.org/0000-0002-9829-5817 et al. (11 more authors) (2018) PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Annals of Oncology (Part of special issue:Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany), 29 (8). viii331-viii331. ISSN 0923-7534

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 The Authors. Published by Elsevier Ltd. All rights reserved. This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.
Dates:
  • Published: October 2018
  • Published (online): 27 January 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) > Clinical & Population Science Dept (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Funding Information:
FunderGrant number
Bristol Myers SquibbPRISM
Depositing User: Symplectic Publications
Date Deposited: 16 Mar 2020 10:05
Last Modified: 16 Mar 2020 10:05
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1093/annonc/mdy283.140
Related URLs:

Share / Export

Statistics